Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. Project Oncology®

The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer

ReachMD Healthcare Image
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Comments
  • Overview

    Non-small cell lung cancer is characterized by various genetic alterations that drive its growth and progression. Fortunately, recent treatment updates, like the FDA approval of sotorasib, adagrasib, amivantamab and mobocertinib, give us the unique opportunity to target these molecular abnormalities. Learn more about these targeted therapies with this brief recap.

Recommended
Details
Comments
  • Overview

    Non-small cell lung cancer is characterized by various genetic alterations that drive its growth and progression. Fortunately, recent treatment updates, like the FDA approval of sotorasib, adagrasib, amivantamab and mobocertinib, give us the unique opportunity to target these molecular abnormalities. Learn more about these targeted therapies with this brief recap.

Schedule5 Oct 2024